Lyell Immunopharma, Inc.LYELEarnings & Financial Report
Nasdaq
NextMar 11, 2026
LYEL Q3 2025 Key Financial Metrics
Revenue
$15.0K
Gross Profit
N/A
Operating Profit
$-37.3M
Net Profit
$-38.8M
Gross Margin
N/A
Operating Margin
-248353.3%
Net Margin
-258973.3%
YoY Growth
-55.9%
EPS
$-2.13
Financial Flow
Lyell Immunopharma, Inc. Q3 2025 Financial Summary
Lyell Immunopharma, Inc. reported revenue of $15.0K for Q3 2025, with a net profit of $-38.8M (-258973.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $15.0K |
|---|---|
| Net Profit | $-38.8M |
| Gross Margin | N/A |
| Operating Margin | -248353.3% |
| Report Period | Q3 2025 |
Lyell Immunopharma, Inc. Annual Revenue by Year
Lyell Immunopharma, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $61.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $61.0K |
| 2023 | $130.0K |
| 2022 | $84.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13000 | $3000 | $13000 | $34000 | $11000 | $7000 | $8000 | $15000 |
| YoY Growth | -100.0% | -95.4% | -51.9% | 36.0% | -15.4% | 133.3% | -38.5% | -55.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $750.0M | $694.2M | $654.1M | $619.2M | $490.9M | $429.8M | $385.5M | $408.0M |
| Liabilities | $95.1M | $91.1M | $87.6M | $88.5M | $108.0M | $93.3M | $86.5M | $78.8M |
| Equity | $655.0M | $603.2M | $566.5M | $530.7M | $382.8M | $336.5M | $298.9M | $329.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-40.6M | $-42.0M | $-38.1M | $-35.0M | $-47.2M | $-54.7M | $-34.5M | $-28.6M |